Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Deodhar

Showing results (121-130 of 272) with videos related to

Pageof 28
Sort By:
The Journal of Rheumatology|December 17, 2017
Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE StudyAtul Deodhar, John D Reveille, Diane D Harrison, et al.
Rheumatology and Therapy|November 16, 2017
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 StudyHasan Tahir, Atul Deodhar, Mark Genovese, et al.
Clinical Rheumatology|July 12, 2022
Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
RMD Open|July 3, 2020
Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world studyP G Conaghan, Rieke Alten, Atul Deodhar, et al.
The Journal of Rheumatology|April 17, 2014
The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trialDésirée van der Heijde, Atul Deodhar, Jürgen Braun, et al.
The Journal of Rheumatology|April 16, 2022
Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA TrialPhilip J Mease, Dafna D Gladman, Joseph F Merola, et al.
Clinical and Experimental Rheumatology|August 28, 2018
Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 studyAtul Deodhar, Philip G Conaghan, Tore K Kvien, et al.
Clinical Rheumatology|June 8, 2022
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
Rheumatology and Therapy|July 21, 2025
Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 StudyChristopher T Ritchlin, Ennio Lubrano, Maria Sole Chimenti, et al.
BMC Rheumatology|September 25, 2021
Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeksAtul Deodhar, Philip Mease, Helena Marzo-Ortega, et al.
Pageof 28

Showing results (121-130 of 272) with videos related to

Sort By:
Pageof 28
The Journal of Rheumatology|December 17, 2017
Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE StudyAtul Deodhar, John D Reveille, Diane D Harrison, et al.
Rheumatology and Therapy|November 16, 2017
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 StudyHasan Tahir, Atul Deodhar, Mark Genovese, et al.
Clinical Rheumatology|July 12, 2022
Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
RMD Open|July 3, 2020
Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world studyP G Conaghan, Rieke Alten, Atul Deodhar, et al.
The Journal of Rheumatology|April 17, 2014
The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trialDésirée van der Heijde, Atul Deodhar, Jürgen Braun, et al.
The Journal of Rheumatology|April 16, 2022
Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA TrialPhilip J Mease, Dafna D Gladman, Joseph F Merola, et al.
Clinical and Experimental Rheumatology|August 28, 2018
Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 studyAtul Deodhar, Philip G Conaghan, Tore K Kvien, et al.
Clinical Rheumatology|June 8, 2022
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
Rheumatology and Therapy|July 21, 2025
Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 StudyChristopher T Ritchlin, Ennio Lubrano, Maria Sole Chimenti, et al.
BMC Rheumatology|September 25, 2021
Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeksAtul Deodhar, Philip Mease, Helena Marzo-Ortega, et al.
Pageof 28